anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A dietary supplement is provided whereby the daily administration of materials derived from the Senegalia plants is provided orally to humans for the purpose of producing or maintaining weight loss as well as improving a person's physical performance and increasing the person's lean muscle mass. The Senegalia materials include these portions of the plant that are normally considered waste or inedible, such as leaves, bark, and roots. The materials contain at least one of the alkaloids from the group consisting of N-methyl-β-phenethylamine; N,N-dimethylphenethylamine; and N-methyl-β-methylphenethylamine. The materials can be administered in their natural form or as extracts, and can be administered in various ways including powders, liquids, capsules and tablets. The Senegalia material may also be used as a tea. For weight loss and weight control, the materials may also be administered concurrently with caloric restriction or in the absence of caloric restriction. The materials may also be administered for the purpose of increasing muscle mass concurrently with a high protein diet as well as an exercise program. More particularly, the present invention relates to the discovery that useful and exploitable levels of these adrenergic amines occur in the plant species of Senegalia.
Benzodiazepines, opioids, and propofol are currently used alone or in combination for achieving sedation during endobronchial ultrasound and other bronchoscopic procedures. However, all these agents carry a risk of respiratory depression. Dexmedetomidine, a highly selective adrenergic alpha-2 agonist, has sedative and analgesic properties but does not cause respiratory depression. This study aims to compare efficacy and safety of dexmedetomidine as a sedative to midazolam in patients with hilar/mediastinal lymphadenopathy undergoing convex-probe endobronchial ultrasonography on day care basis. Patients will be randomized to receive either dexmedetomidine plus fentanyl or midazolam plus fentanyl prior to procedure, followed by dexmedetomidine or saline infusion respectively during the procedure. Ramsay sedation score of two will be targeted, failing which patients in both groups will receive midazolam bolus on as-needed basis. Bronchoscopist will remain blinded to group allocation. Patients will be monitored for sedation, oxygenation and hemodynamic parameters throughout. Need for additional midazolam, sedative efficacy, frequency of adverse respiratory and hemodynamic events, and bronchoscopist and patient satisfaction with the procedure will be compared between the two groups.
PURPOSE OF REVIEW: Recent advancements in the management of clinical stage II (CS II) testicular cancer have transformed it into a predominantly curable condition. This success in treatment advancements has markedly extended patient survival. However, these treatments carry risks and morbidities, which is important to consider given the disease's impact on young men and the emerging understanding of long-term treatment consequences.
RECENT FINDINGS: Emerging data support primary retroperitoneal lymph node dissection (RPLND) for select CS II seminoma patients, with similar short-term outcomes to chemotherapy but less treatment intensity. Recent studies have also challenged the reflexive use of adjuvant chemotherapy for pathologic node-positive disease, as growing evidence shows low relapse rates regardless of nodal stage. Furthermore, novel biomarkers like circulating serum microRNA-371a-3p levels can help predict the presence of viable germ cell tumor at time of RPLND.
SUMMARY: Advances in risk stratification and therapy enable personalized de-escalation approaches for oligometastatic testicular cancer, optimizing survivorship. Upfront RPLND, reassessing adjuvant systemic therapy for RPLND pN+ disease, and novel biomarkers will shape precision treatment to achieve high cure rates with excellent quality of life. Ongoing trials of reduced-intensity regimens, accurate prognostic models, improved surgical strategy, and emerging biomarkers represent the next frontier in tailored curative therapy.
Non-cirrhotic participants take grazoprevir (50 mg or 100 mg dose selected from Part I) and 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 2 and are followed-up for 24 weeks during the open-label period of Part 2.
The present invention provides a long-term continuous multivariate measurement and multivariate physiological parameter relative dynamic change curve pattern analysis of early warning monitoring wearable device system, which can be used for the officers workers in the (but not limited to) offices or production lines or the people at home. This system consist of the wearable chipset, multi-element sensor unit for long-term continuity measurement of multi-element physiological parameters, and the analysis software unit for analysis of multi-element sensor unit signals, as well as Mcu unit for accepting multi-element physiological parameters of multi-element sensor unit for long-term continuous multi-element measurement, relative quantitative analysis and use wireless to transmit its analysis results to a control center. The control center will generates an early warning guardianship signal after receiving the Mcu signal, after processing the telecommunications to notify the relevant guardian or the relevant supervisory unit. Different from the general discontinuous test method, which only measure separately the average warning point (such as the temperature 37.2OC) and issue the warning. Our system is to analysis the different grade’s slope changes of the continuous curve as well as the environment curves of various physiological parameters of individual epidemics for a long time measurements. The enviroment parameters (such as room temperature) are also measured at the same time and AI deep learning modeling is builded up. So that AI analysis and judgment can issue an early warning.
PURPOSE: In this article, we comprehensively review the current situation and research on technology related to outdoor travel for blind and visually impaired people (BVIP), given the diverse types and incomplete functionality of navigation aids for the blind. This aims to provide a reference for related research in the fields of outdoor travel for BVIP and blind navigation.
MATERIALS AND METHODS: We compiled articles related to blind navigation, of which a total of 227 of them are included in the search criteria. One hundred and seventy-nine articles are selected from the initial set, from a technical point of view, to elaborate on five aspects of blind navigation: system equipment, data sources, guidance algorithms, optimization of related methods, and navigation maps.
RESULTS: The wearable form of assistive devices for the blind has the most research, followed by the handheld type of aids. The RGB data class based on vision sensor is the most common source of navigation environment information data. Object detection based on picture data is also particularly rich among navigation algorithms and associated methods, indicating that computer vision technology has become an important study content in the field of blind navigation. However, research on navigation maps is relatively less.
CONCLUSIONS: In the study and development of assistive equipment for BVIP, there will be an emphasis on prioritizing attributes, such as lightness, portability, and efficiency. In light of the upcoming driverless era, the research focus will be on the development of visual sensors and computer vision technologies that can aid in navigation for the blind.
The present invention provides one new kind of compound, solasodine hydriodide, with obvious anticancer and asthma relieving effects, less toxic side effect, stable property and high dissolubility. The molecular expression is shown. The present invention also relates to the preparation process of solasodine hydriodide with black nightshade, Australia eggplant or yellowfruit nightshade as material. The preparation process includes acid leaching and precipitating to obtain total alkaloid. The preparation process of the present invention has low reagent cost, no environmental pollution, short production period, high product purity and other advantages. The present invention also relates to the application of solasodine hydriodide in preparing medicine for treating cancer and relieving asthma, etc.
BACKGROUND: Plasmodium vivax remains a major challenge for malaria control and elimination due to its ability to cause relapsing illness. To prevent relapses the Indian National Center for Vector Borne Diseases Control (NCVBDC) recommends treatment with primaquine at a dose of 0.25 mg/kg/day provided over 14 days. Shorter treatment courses may improve adherence and treatment effectiveness.
METHODS: This is a hospital-based, randomised, controlled, open-label trial in two centres in India. Patients above the age of 16 years, with uncomplicated vivax malaria, G6PD activity of ≥ 30% of the adjusted male median (AMM) and haemoglobin levels ≥ 8 g/dL will be recruited into the study and randomised in a 1:1 ratio to receive standard schizonticidal treatment plus 7-day primaquine at 0.50 mg/kg/day or standard care with schizonticidal treatment plus 14-day primaquine at 0.25 mg/kg/day. Patients will be followed up for 6 months. The primary endpoint is the incidence risk of any P. vivax parasitaemia at 6 months. Safety outcomes include the incidence risk of severe anaemia (haemoglobin < 8 g/dL), the risk of blood transfusion, a > 25% fall in haemoglobin and an acute drop in haemoglobin of > 5 g/dL during primaquine treatment.
DISCUSSION: This study will evaluate the efficacy and safety of a 7-day primaquine regimen compared to the standard 14-day regimen in India. Results from this trial are likely to directly inform national treatment guidelines.
TRIAL REGISTRATION: Trial is registered on CTRI portal, Registration No: CTRI/2022/12/048283.
Morbidity and mortality during chemotherapy in older adults with haematological malignancy can be unpredictable. The Haemato-Oncology Frailty (HOF) score was previously found to predict outcomes in a cohort of patients with plasma cell myeloma. In this study, we assess its utility in assessing frailty in patients with lymphoma, and compare its performance to that of two other frailty scores. The HOF score was able to predict progression-free survival in this population, and was also shown to have potential in assessing the dynamism of frailty during chemotherapy. It performed well when compared to the Charlson Comorbidity Index (CCI) score and the Haematopoietic Cell Transplantation-Specific Comorbidity Index (HCTCI), although the study was not powered to assess for non-inferiority. The HOF score is a new score with the potential for application in different haematological malignancies.
The invention relates to homogeneous preformulations containing high concentrations of steroids which are suitable for producing low-dose solid and semi-solid pharmaceutical preparations with a steroid concentration of between 0.001 and 1 weight percent. Said preformulations are obtained by evaporating the dispersing agent containing the steroidal active ingredient from a suspension containing the usual pharmaceutical additives. To this end, a spray mist is produced in which the average drop diameter is greater than the average diameter of the additive particles, and the maximum grain size of the dried particles of the steroidal preformulation is increased by less than 30 % in relation to the grain size of the additive. Said preformulations are characterised by their homogenity and resistance to demixing, whereby the steroidal active ingredient is finely dispersed and integrally bonded to the additive. Surprinsingly it was discovered that these types of steroidal preformulations, in comparison with conventional methods, can be processed without difficulty into low-dose pharmaceutical preparations with very good homogeneity and active ingredient stability. The method for producing homogeneous steroid preformulations for low-dose solid and semi-solid pharmaceutical preparations with a steroid concentration of between 0.001 and 1 weight percent stands out among other things by the fact that the active ingredient and additive particles from the atomized suspension are not dried one next to the other. The choice of processing conditions during atomization makes it possible for practically all the active ingredient to be bonded integrally to the additive.
Oral lipoic acid is an antioxidant that helps proteins work in the body. It is available in oral and intravenous formulations and has been used in the past to treat nerve damage like that seen in diabetes and some other metabolic disorders. It is available as a dietary supplement in the United States.

Patients with a diagnosis of acute optic neuritis who are enrolled in the study will undergo medical and nervous system examinations, and blood draws. The study doctor will take a medical history and perform physical examinations. Research assistants at the MS Center, who are trained in blood draws, will perform the blood draws. Patients will also undergo Optical coherence tomography (OCT) examination at Casey Eye Institute, and receive two MRIs at Oregon Health and Science University (OHSU). Because it is a placebo-controlled trial, subjects will have a 50:50 chance of receiving either placebo (inactive) or study drug. If enrolled in the study, patients will take two gel capsules of the study drug or placebo at the same time every day for six weeks.
INTRODUCTION AND HYPOTHESIS: The objective was to evaluate the clinically beneficial effect of adding transvaginal monopolar non-ablative radiofrequency (RF) to pelvic floor muscle training (PFMT) on leakage severity, quality of life and urinary incontinence-related symptoms in women with stress urinary incontinence (SUI).
METHODS: A double-blind randomised controlled trial was conducted, with a 6-week intervention and a 6-month follow-up. Participants were randomly assigned to the experimental group (PFMT plus RF; n = 18) or the control group (PFMT plus placebo; n = 20). The primary outcome was the International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF). Secondary outcomes included the Pelvic Floor Distress Inventory-20 (PFDI-20) and the Pelvic Floor Impact Questionnaire-7 (PFIQ-7), self-efficacy, female sexual function, pelvic floor muscle dynamometry, 1-h pad test and number of SUI episodes per week. Inferential analyses of the data were performed using a two-factor analysis of variance.
RESULTS: Both groups achieved a statistically significant improvement in ICIQ-SF over time. However, the differences observed in the experimental group exceeded the minimal clinically important differences by 4 points (MD = -9.4, 95% CI = -12.6 to -6.3), which was not observed in the control group (MD = -3.9, 95% CI = -6.9 to -1.0). This was maintained at the 6-month follow-up with a significant time*group interaction (p < 0.001, ηp2 = 0.150). There was no time*group interaction in the other variables (p > 0.05). Additionally, a significant difference in favour of the experimental group was observed in the 1-h pad test and episodes of SUI per week (p < 0.05).
CONCLUSIONS: This study highlights the beneficial effects of adding transvaginal RF to PFMT on the severity and amount of leakage, as well as on the quality of life and urinary incontinence-related symptoms in women with moderate SUI. Future trials are needed to assess the effects of this intervention in women with severe SUI.
Hyperlipidemia (lipid infusion) will receive an I.V. Lipid infusion with a co-infusion of ascorbic acid or placebo at your visit 2 and the alternative treatment of ascorbic acid or placebo will be given on the subsequent study visit 3.
An apparatus for generating a quantifier of cognitive skills in an individual includes a user interface, a memory to store processor-executable instructions, and a processing unit communicatively coupled to the user interface and the memory. Upon execution of the processor-executable instructions by the processing unit, the processing unit is configured to: render a first instance of a task with an interference at the user interface, requiring a first response from the individual to the first instance of the task in the presence of the interference and a response from the individual to at least one evocative element. One or more of the first instance of the task and the interference comprises the at least one evocative element. The user interface is configured to measure data indicative of the response of the individual to the at least one evocative element, the data comprising at least one measure of emotional processing capabilities of the individual under emotional load. The apparatus is configured to measure substantially simultaneously the first response from the individual to the first instance of the task and the response from the individual to the at least one evocative element. The processing unit is further configured to receive data indicative of the first response and the response of the individual to the at least one evocative element. The processing unit is further configured to analyze the data indicative of the first response and the response of the individual to the at least one evocative element to compute at least one performance metric comprising at least one quantified indicator of cognitive abilities of the individual under emotional load.
PROBLEM TO BE SOLVED: To obtain an effusive preparation capable of effusing an active ingredient into water or warm water, simply and surely administrable. SOLUTION: This baggy effusive preparation is obtained by housing or retaining a medicine 7 in at least one water-permeable bag 2. The water- permeable bag 2 may contain a knobbing part 4 or may be a stick-like bag body having a reinforcing part 6 in the longer direction. A preparation like this can be pharmaceutically manufactured without using a carrier (excipient, binder, disintegrator, etc.), even in an extremely small amount of an active ingredient. The effusive preparation may have a multiple bag structure composed of plural water-permeable bags. The preparation of the multiple bag structure is obtained by housing a medicine in a water-permeable bag, storing a masking agent in another water-permeable bag so that the bitterness of the medicine may be alleviated.  Repelling components to be formulated are individually housed or retained in water-permeable bags, respectively to improve the stability of the active ingredient. The water-permeable bag may be housed in an openable and closable outer bag having gas barrier properties.
INTRODUCTION: The superficial and deep parasternal intercostal plane (DPIP) blocks are two new blocks for thoracic pain. There are limited cadaveric studies evaluating the dye spread with these blocks. In this study, we examined the dye spread of an ultrasound-guided DPIP block in a human cadaveric model.
METHODS: Five ultrasound-guided DPIP blocks were performed in four unembalmed human cadavers using an in-plane approach with a linear transducer oriented in a transverse plane adjacent to the sternum. Twenty milliliters of 0.1% methylene blue were injected between ribs 3 and 4 into the plane deep to the internal intercostal muscles and superficial to the transversus thoracis muscle layer. The chest muscles were dissected, and the extent of dye spread was documented in both cephalocaudal and mediolateral directions.
RESULTS: The transversus thoracis muscle slips were stained in all cadavers from 4 to 6 levels. Intercostal nerves were dyed in all specimens. Four levels of intercostal nerves were dyed in each specimen with variability in number of levels stained above and below the level of the injection.
CONCLUSIONS: The DPIP block spreads along the tissue plane above the transversus thoracis muscles to multiple levels to dye the intercostal nerves in this cadaver study. This block may be of clinical value for analgesia in anterior thoracic surgical procedures.
FIELD: oncology. SUBSTANCE: phthalocyanine aluminum chloride is subjected to sulfochlorination with chlorosulfonic acid at their weight ratio 1:10 and temperature 115-118 C. Purification of thus obtained sulfonic acids is accomplished by boiling in dilute hydrochloric acid and then in isopropyl alcohol. Purified sulfonic acids are converted into sodium salts and their solutions are treated with activated carbon and sterilized by microfiltering. Finally solutions are dried at 108-110 C under sterile conditions. EFFECT: enabled preparation of light sensitizer characterizing by sterility and anti-inflammatory property. 2 ex
Laser ablation therapy (LA) uses Indocyanine Green dye (ICG) which efficiently absorbs laser energy and the increased temperature results in an instantaneous flame that chars tissue and microbes. Photodynamic therapy (PDT) uses different dyes that are activated by light to kill bacteria. This study evaluated the biocompatibility of the dye Curcumin (CUR), Methylene Blue (MB), and Indocyanine Green (ICG) before and after laser activation (ACT). Polyethylene tubes containing one of the dyes were implanted in the subcutaneous tissue of 32 rats (4 tubes per rat) which were divided into 8 groups: C - control (saline solution); C + ACT (Red Laser 660 nm); CUR; CUR + ACT (480 nm blue LED); MB; MB + ACT (Red Laser 660 nm); ICG; ICG + ACT (810 nm Infrared Laser). After 7 and 30 days (n = 8/time), the rats were euthanized and the tubes with the surrounding tissue were removed and processed for histological analysis of inflammation using H&E stain, and collagen fiber maturation using picrosirius red (PSR). A two-way analysis of variance statistical test was applied (p < 0.05). At 7 days, regardless of laser activation, the CUR group showed a greater inflammatory infiltrate compared to the ICG and control groups, and the MB group had a greater inflammation only in relation to the control (p < 0.05). At 30 days, CUR and MB groups showed a greater inflammatory infiltrate than the control (p < 0.05). ICG group was equal to the control in both periods, regardless of the laser activation (p > 0.05). Laser activation induced the proliferation of collagen immature fibers at 7 days, regardless of the dye (p < 0.05). The CUR group showed a lower percentage of immature and mature fibers at 7 days, compared to ICG and control (p < 0.05) and, at 30 days, compared to control (p < 0.05). Regardless of laser activation, the ICG showed the results of collagen maturation closest to the control (p > 0.05). It was concluded that all dyes are biocompatible and that laser activation did not interfere with biocompatibility. In addition, the maturity of collagen was adequate before and after the laser activation. These results demonstrate that the clinical use of dyes is safe even when activated with a laser.